LT3352754T - Aldozės reduktazės inhibitoriai ir jų naudojimo būdai - Google Patents

Aldozės reduktazės inhibitoriai ir jų naudojimo būdai

Info

Publication number
LT3352754T
LT3352754T LTEP17816127.9T LT17816127T LT3352754T LT 3352754 T LT3352754 T LT 3352754T LT 17816127 T LT17816127 T LT 17816127T LT 3352754 T LT3352754 T LT 3352754T
Authority
LT
Lithuania
Prior art keywords
reductase inhibitors
aldose reductase
aldose
inhibitors
reductase
Prior art date
Application number
LTEP17816127.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Andrew Wasmuth
Donald W. Landry
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of LT3352754T publication Critical patent/LT3352754T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cosmetics (AREA)
LTEP17816127.9T 2016-06-21 2017-06-21 Aldozės reduktazės inhibitoriai ir jų naudojimo būdai LT3352754T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352784P 2016-06-21 2016-06-21
PCT/US2017/038505 WO2017223179A1 (en) 2016-06-21 2017-06-21 Aldose reductase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
LT3352754T true LT3352754T (lt) 2021-02-25

Family

ID=60783884

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17816127.9T LT3352754T (lt) 2016-06-21 2017-06-21 Aldozės reduktazės inhibitoriai ir jų naudojimo būdai
LTEP20188323.8T LT3757107T (lt) 2016-06-21 2017-06-21 4-okso-3,4-dihidrotieno[3,4-d]piridazino junginiai, kaip aldozės reduktazės inhibitoriai, ir jų panaudojimo būdai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP20188323.8T LT3757107T (lt) 2016-06-21 2017-06-21 4-okso-3,4-dihidrotieno[3,4-d]piridazino junginiai, kaip aldozės reduktazės inhibitoriai, ir jų panaudojimo būdai

Country Status (22)

Country Link
US (6) US10150779B2 (cg-RX-API-DMAC7.html)
EP (3) EP3352754B1 (cg-RX-API-DMAC7.html)
JP (4) JP6895464B2 (cg-RX-API-DMAC7.html)
CN (2) CN109310674B (cg-RX-API-DMAC7.html)
AU (3) AU2017281082B2 (cg-RX-API-DMAC7.html)
CA (1) CA3025081A1 (cg-RX-API-DMAC7.html)
DK (2) DK3757107T3 (cg-RX-API-DMAC7.html)
ES (2) ES2836500T3 (cg-RX-API-DMAC7.html)
FI (1) FI3757107T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20201905T1 (cg-RX-API-DMAC7.html)
HU (2) HUE052101T2 (cg-RX-API-DMAC7.html)
IL (3) IL304979A (cg-RX-API-DMAC7.html)
LT (2) LT3352754T (cg-RX-API-DMAC7.html)
MX (2) MX391561B (cg-RX-API-DMAC7.html)
NZ (1) NZ748506A (cg-RX-API-DMAC7.html)
PL (1) PL3757107T3 (cg-RX-API-DMAC7.html)
PT (2) PT3757107T (cg-RX-API-DMAC7.html)
RS (1) RS61239B1 (cg-RX-API-DMAC7.html)
SG (2) SG10202012188VA (cg-RX-API-DMAC7.html)
SI (2) SI3757107T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017223179A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808506B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
HUE052101T2 (hu) * 2016-06-21 2021-04-28 Univ Columbia Aldóz reduktáz inhibitorok és ezek alkalmazása
IL272246B1 (en) * 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
WO2020167937A1 (en) * 2019-02-12 2020-08-20 Applied Therapeutics, Inc. Methods for treating cutaneous aging
JP7623292B2 (ja) 2019-04-01 2025-01-28 アプライド セラピューティクス, インコーポレイテッド アルドースレダクターゼの阻害剤
CA3136100A1 (en) 2019-05-07 2020-11-12 Stephan L. ZUCHNER Treatment and detection of inherited neuropathies and associated disorders
CN120093757A (zh) * 2019-10-08 2025-06-06 应用治疗公司 用于治疗磷酸甘露变位酶2缺乏的醛糖还原酶抑制剂
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
KR20230005944A (ko) * 2020-05-01 2023-01-10 어플라이드 테라퓨틱스 인크. 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
US20240033263A1 (en) * 2021-03-18 2024-02-01 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2025219948A1 (en) 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) * 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
IL80475A (en) 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
CA1299178C (en) 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
WO1989006651A1 (en) * 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
FI922308A7 (fi) 1989-12-15 1992-05-21 Pfizer Substituoituja oksoftalatsinyylietikkahappoja ja niiden anologeja
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
JP2789134B2 (ja) * 1992-09-28 1998-08-20 ファイザー・インク. 糖尿病の合併症を制御する置換ピリミジン類
CA2227691A1 (en) 1995-08-28 1997-03-06 American Home Products Corporation Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents
EP1017697A1 (en) 1997-09-23 2000-07-12 Novo Nordisk A/S MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
AU774929B2 (en) 1998-03-31 2004-07-15 Institutes For Pharmaceutical Discovery, Llc, The Substituted indolealkanoic acids
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
PT1373259E (pt) 2001-03-30 2005-03-31 Pfizer Prod Inc Inibidores piridazinona de aldose reductase
JP2005527492A (ja) 2002-01-23 2005-09-15 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニスト
US20040047919A1 (en) 2002-06-13 2004-03-11 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
OA12867A (en) * 2002-06-14 2006-09-15 Takeda Pharmaceutical Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. pepticulcers.
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
WO2006078717A2 (en) 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
PL3597650T3 (pl) 2010-07-16 2023-02-06 The Trustees Of Columbia University In The City Of New York Inhibitory reduktazy aldozy i ich zastosowania
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
HUE052101T2 (hu) * 2016-06-21 2021-04-28 Univ Columbia Aldóz reduktáz inhibitorok és ezek alkalmazása
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection

Also Published As

Publication number Publication date
MX391561B (es) 2025-03-21
RU2019101194A3 (cg-RX-API-DMAC7.html) 2020-08-31
US10647726B2 (en) 2020-05-12
JP6895464B2 (ja) 2021-06-30
IL263631A (en) 2019-01-31
CN115160339A (zh) 2022-10-11
US11498925B2 (en) 2022-11-15
EP4316603A2 (en) 2024-02-07
CN115160339B (zh) 2024-05-14
SG10202012188VA (en) 2021-01-28
BR112018076244A2 (pt) 2019-03-26
RU2019101194A (ru) 2020-07-23
US10150779B2 (en) 2018-12-11
WO2017223179A1 (en) 2017-12-28
CN109310674B (zh) 2022-07-08
JP2025124733A (ja) 2025-08-26
PT3352754T (pt) 2020-12-07
HRP20231563T1 (hr) 2024-03-15
IL283809B2 (en) 2024-01-01
US20230312599A1 (en) 2023-10-05
SI3352754T1 (sl) 2021-03-31
JP2021130719A (ja) 2021-09-09
HK1259379A1 (en) 2019-11-29
SG11201810642XA (en) 2019-01-30
ZA201808506B (en) 2020-05-27
JP2019518779A (ja) 2019-07-04
MX2018016122A (es) 2019-08-01
IL283809B1 (en) 2023-09-01
CA3025081A1 (en) 2017-12-28
NZ748506A (en) 2025-07-25
IL263631B (en) 2021-07-29
HUE064911T2 (hu) 2024-04-28
EP3352754B1 (en) 2020-09-02
FI3757107T3 (fi) 2023-12-12
EP3757107A1 (en) 2020-12-30
ES2836500T3 (es) 2021-06-25
PT3757107T (pt) 2023-12-14
DK3757107T3 (da) 2023-11-27
SI3757107T1 (sl) 2024-02-29
CN109310674A (zh) 2019-02-05
AU2021203801A1 (en) 2021-07-15
US20180237451A1 (en) 2018-08-23
HRP20201905T1 (hr) 2021-01-22
LT3757107T (lt) 2023-12-11
US20210284652A1 (en) 2021-09-16
AU2017281082A1 (en) 2018-12-06
EP3757107B1 (en) 2023-10-25
IL283809A (en) 2021-07-29
US20200283451A1 (en) 2020-09-10
JP2023171614A (ja) 2023-12-01
HUE052101T2 (hu) 2021-04-28
EP3352754A1 (en) 2018-08-01
JP7688681B2 (ja) 2025-06-04
EP3352754A4 (en) 2019-04-17
PL3757107T3 (pl) 2024-03-18
EP4316603A3 (en) 2024-04-17
US20250163073A1 (en) 2025-05-22
MX2021014938A (es) 2022-01-24
AU2021203801B2 (en) 2023-04-06
US12077547B2 (en) 2024-09-03
DK3352754T3 (da) 2020-12-07
ES2966094T3 (es) 2024-04-18
AU2017281082B2 (en) 2021-03-18
AU2023204218A1 (en) 2023-07-27
IL304979A (en) 2023-10-01
US10870658B2 (en) 2020-12-22
RS61239B1 (sr) 2021-01-29
US20190300543A1 (en) 2019-10-03
JP7368419B2 (ja) 2023-10-24
AU2023204218B2 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
LT3352754T (lt) Aldozės reduktazės inhibitoriai ir jų naudojimo būdai
LT3205650T (lt) Egfr inhibitorius ir jo gavimas bei taikymas
LT3368534T (lt) Valbenazino ditozilatas ir jo polimorfai
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3443009T (lt) Anti-tim-3 antikūnai ir kompozicijos
IL280863A (en) Autotaxin inhibitors and uses thereof
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3258951T (lt) Anti-pvrig antikūnai ir jų panaudojimo būdai
EP3411412A4 (en) FIT-IMMUNOGLOBULIN TECHNOLOGY AND USES THEREOF
LT3448386T (lt) Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas
LT3215532T (lt) Anti-tim3 antikūnai ir jų naudojimo būdai
LT3394065T (lt) Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
LT3177608T (lt) Proteinkinazės c inhibitoriai ir jų naudojimo būdai
LT3331877T (lt) Pirazolpirimidino dariniai ir jų panaudojimas
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
LT3126388T (lt) Antikūnai prieš egfrviii ir jų panaudojimo būdai
LT3122359T (lt) Fgfr inhibitoriaus ir igf1r inhibitoriaus deriniai
LT3491025T (lt) Fcrn antikūnai ir jų panaudojimo būdai
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
EP3426244C0 (en) 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND THEIR USES
EP3884939C0 (en) 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND THEIR USES
DK3678293T3 (da) Forstærker
EP3459937A4 (en) THIAZONE DERIVATIVE AND APPLICATIONS